2015: which new directions for Alzheimer’s disease?

2015: which new directions for Alzheimer’s disease?

Bibliographic Details
Main Authors:	Xénia eLATYPOVA, Ludovic eMARTIN
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-12-01
Series:	Frontiers in Cellular Neuroscience
Subjects:	Dementia Therapeutics tau abeta Alzheimer's disease (AD)
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00417/full

Similar Items

Alternative neural circuitry that might be impaired in the development of Alzheimer disease
by: Jesus eAvila, et al.
Published: (2015-04-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

The Roles of Lipid and Glucose Metabolism in Modulation of β-Amyloid, Tau, and Neurodegeneration in the Pathogenesis of Alzheimer disease
by: Naoyuki eSato, et al.
Published: (2015-10-01)

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease
by: Liana G. Apostolova, et al.
Published: (2014-01-01)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease
by: Lambracht-Washington D, et al.
Published: (2013-08-01)

Possible Modification of Alzheimer Disease by Statins in Midlife: Interactions with Genetic and Non-Genetic Risk Factors
by: Mitsuru eShinohara, et al.
Published: (2014-04-01)

Study of Histopathological Lesions in CA1 of the Hippocampus after Injection of Beta-Amyloid in a Rat Model of Alzheimer’s Disease
by: SM Hoseini,, et al.
Published: (2012-07-01)

Molecular Mechanisms of Cognitive Dysfunction following Traumatic Brain Injury
by: Kendall Rae Walker, et al.
Published: (2013-07-01)

Opposite changes in APP processing and human Aβ levels in rats carrying either a protective or a pathogenic APP mutation
by: Marc D Tambini, et al.
Published: (2020-02-01)

Axonal generation of amyloid-β from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes
by: Raja Bhattacharyya, et al.
Published: (2021-05-01)

Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus
by: Tony Valente, et al.
Published: (2010-01-01)

Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits
by: Shreyasi Chatterjee, et al.
Published: (2018-06-01)

Microglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
by: Victoria Navarro, et al.
Published: (2018-05-01)

Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease
by: DEFELICE FERNANDA G., et al.
Published: (2002-01-01)

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
by: David A. Loeffler
Published: (2020-05-01)

Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease
by: Tânia Soares Martins, et al.
Published: (2021-04-01)

White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review
by: Frank R. Sharp, et al.
Published: (2023-02-01)

PET Imaging of Tau Pathology: Towards an affirmative diagnosis of Alzheimer’s and Tauopathies
by: Olga eJames, et al.
Published: (2015-03-01)

Design, Synthesis, and Validation of a Novel [<sup>11</sup>C]Promethazine PET Probe for Imaging Abeta Using Autoradiography
by: Clayton A. Whitmore, et al.
Published: (2021-04-01)

Pathological Tau From Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo
by: Jin Miao, et al.
Published: (2019-03-01)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
by: Fernando Gonzalez-Ortiz, et al.
Published: (2023-03-01)

Alzheimer’s disease models and functional genomics - How many needles are there in the haystack?
by: Jurgen eGotz, et al.
Published: (2012-08-01)

Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis
by: Allie N. Greene, et al.
Published: (2022-10-01)

Editorial: Current advances in genetic dementia and aging
by: Yuzhen Xu, et al.
Published: (2022-09-01)

Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
by: John S. Tzartos, et al.
Published: (2022-08-01)

Mouse Models of Alzheimer’s Disease
by: Miyabishara Yokoyama, et al.
Published: (2022-06-01)

Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
by: Teresa Pardo-Moreno, et al.
Published: (2022-05-01)

Clinical effects of novel susceptibility genes for beta-amyloid: a gene-based association study in the Korean population
by: Bo-Hyun Kim, et al.
Published: (2023-10-01)

Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
by: Hansen Wang, et al.
Published: (2017-06-01)

Trilateral association of autophagy, mTOR and Alzheimer’s disease: Potential pathway in the development for Alzheimer’s disease therapy
by: Arunkumar Subramanian, et al.
Published: (2022-12-01)

Alzheimer's disease - the role of nurses in patient care
by: Patrycja Polańska, et al.
Published: (2019-06-01)

Alzheimer's disease - the role of nurses in patient care
by: Patrycja Polańska, et al.
Published: (2019-06-01)

Update on Alzheimer’s Disease
by: Kurt A. Jellinger
Published: (2015-08-01)

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD
by: E. G. B. Vijverberg, et al.
Published: (2021-08-01)

A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies
by: Caterina Giacomini, et al.
Published: (2018-05-01)

Roles of Vascular and Metabolic Components in Cognitive Dysfunction of Alzheimer disease: Short- and Long-term Modification by Non-genetic Risk Factors
by: Naoyuki eSato, et al.
Published: (2013-11-01)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
by: Alejandro R Roda, et al.
Published: (2022-01-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)

Nanomaterials in Alzheimer’s disease treatment: a comprehensive review
by: Maryam Faiyaz, et al.
Published: (2021-10-01)

Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines
by: Philipp Spitzer, et al.
Published: (2020-09-01)